This news release contains updated and new data not in abstract MDP234.

Research Highlights:

  • Treating hypertension to achieve a lower blood pressure goal — a systolic (top) number of 120 instead of 140 mm Hg — could add a year or more to the life spans of middle-aged or older adults, according to a new analysis of the SPRINT trial.
  • A separate analysis of treating more people according to updated hypertension guidelines finds the greatest cost-effectiveness over a decade by targeting older adults with heart disease.

Embargoed until 4 a.m. CT/5 a.m. ET Monday, Nov. 11, 2019

DALLAS, Nov. 11, 2019 — Two studies examining the benefits and costs of treating high blood pressure more intensively, by aiming for lower blood pressure measures, will be presented at the American Heart Association’s Scientific Sessions 2019 — November 16-18 in Philadelphia. The Association’s Scientific Sessions is an annual, premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

A separate study analyzed the cost effectiveness of incrementally implementing high blood pressure treatment according to the 2017 American College of Cardiology/American Heart Association blood pressure guidelines to subgroups in order from highest to lowest risk of cardiovascular events and showed that targeting the highest risk patients would be cost-effective over 10 years.

Globally, an estimated 1.13 billion people have high blood pressure, or hypertension, which causes about 13% of all deaths, according to the World Health Organization. Almost 1,000 people in the U.S. die each day with high blood pressure as a primary or contributing cause, according to data from the Centers for Disease Control and Prevention. 

Effect of Intensive Blood Pressure Control on Residual Life Span in the SPRINT Trial (Poster Presentation MDP233)

The research into hypertension care and life span found that with more intensive blood pressure control, focused on a target systolic blood pressure of less than 120 mm Hg, a 50-year-old could expect to live almost three years longer. In order to achieve the lower blood pressure target, patients adopted healthy lifestyle habits and took blood pressure medications as prescribed.

“These are important steps to prolong your life free from disease or disability,” said lead study author Muthiah Vaduganathan, M.D., M.P.H., an instructor of medicine at Harvard Medical School and associate physician at Brigham and Women’s Hospital in Boston. Brian Claggett, Ph.D., assistant professor of medicine at Harvard Medical School, was the study’s co-first author and initially developed these methods to estimate long-term benefits of interventions tested in shorter clinical trials.

At age 65, intensive treatment could extend life by more than a year, the research estimated. With intensive treatment, an 80-year-old would be expected to add almost 10 months to his or her life span.

“High blood pressure has been implicated as one of the reasons for stalled progress in reducing heart disease-related deaths in the United States,” Vaduganathan said. “These data reinforce that tighter blood pressure control, especially when started earlier in life, may meaningfully prolong life span.”

The new study builds on the 2015 findings of the landmark Systolic Blood Pressure Intervention Trial, or SPRINT, which tested the value of treating blood pressure intensively to reduce systolic readings to a lower target — below 120 mm Hg, instead of the routinely used target of below 140 mm Hg. SPRINT, which followed patients for up to six years, found that the intensive approach reduced patients’ risk of cardiovascular events by 25%. These events included heart attack, stroke, heart failure and cardiovascular-related death.

SPRINT enrolled middle-aged and older adults with systolic readings of 130 to 180 mm Hg, who were at risk of heart disease but did not have diabetes. Patients were considered at high risk of heart disease if they had at least one of the following: evidence of cardiovascular disease other than stroke, a high 10-year cardiovascular risk score, chronic kidney disease or if they were age 75 or older. In this analysis, SPRINT data was evaluated to project the full life spans for patients treated intensively to meet the lower blood pressure target of 120 mm Hg and for those who received standard care (systolic blood pressure target of less than 140 mm Hg).  

Across age groups, intensive treatment for high blood pressure lengthened patients’ remaining life span by 4% to 9%, compared with standard care, the study found. “In contrast with the oldest patients, middle-aged patients had the greater absolute benefit because they start with a longer expected life span and can receive the intensive treatment over a longer period of time,” Vaduganathan said.

“This analysis of the [SPRINT] trial suggests that there’s additional years of life that can be added by more aggressive control of blood pressure,” said Mitchell S.V. Elkind, M.D., American Heart Association president-elect, Chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association, and professor of neurology and epidemiology at Columbia University in New York. “When you tell people that lowering their blood pressure is going to reduce their chance of having a stroke or a heart attack, by 25%, which is what [SPRINT] showed, but what does that number mean, in real terms? This analysis suggests that for a man who is 50 years old, that lowering blood pressure to [the lower blood pressure] targets, could extend your lifespan by 3 years, on average.”

Co-authors are Brian L. Claggett, Ph.D. (co-first author); Stephen P. Juraschek, M.D.; and Scott D. Solomon, M.D. Author disclosures are in the abstract.

Cost-Effectiveness of Treating Hypertension According to 2017 American College of Cardiology / American Heart Association Hypertension Guidelines (Poster Presentation MDP234)

The cost-effectiveness study explored how best to implement recent guidelines from the ACC/AHA, which lowered blood pressures defining hypertension from readings of 140/90 mm Hg or higher to 130/80 mm Hg or higher. In addition to treating all adults with blood pressures 140/90 mm Hg or higher, the 2017 guidelines recommend medication therapy for selected patients with blood pressures ranging 130-139/80-89 mm Hg if they have had a cardiovascular event such as a heart attack or stroke or are at high risk for a first event within 10 years.

“Compared with hypertension guidance from the 2003 Seventh Report of the Joint National Committee, the 2017 ACC/AHA guidelines increased the number of people diagnosed and eligible for hypertension treatment and recommended blood pressure targets of <130/80 mm Hg for all patients,” said the study’s first author, Joanne M. Penko, M.S., M.P.H., a research data analyst at the University of California, San Francisco.

The authors evaluated the cost-effectiveness of implementing the 2017 ACC/AHA guidelines over 10 years, compared with the 2003 Seventh Report guidelines, including hypertension treatment costs incurred (prescription medications and monitoring visits) along with healthcare costs avoided by preventing heart disease and stroke events. Quality-adjusted life years (QALYs) quantified health that would be gained by implementing the 2017 hypertension guidelines. The ACC and the AHA consider healthcare strategies with a cost per QALY gained below $50,000 to have a high value, those ranging from $50,000 to $150,000 per QALY to have intermediate value, and those with costs higher than $150,000 per QALY to be low value.

This analysis comparing the 2017 guidelines to the 2003 guidelines found:

  • Treating all adults 35 to 84 years of age according to the 2017 hypertension guidelines was a high to intermediate value treatment in some, but not all men, and a generally lower value strategy for women.

  • Adding the more aggressive treatment goals of the 2017 guidelines was highly cost-effective over 10 years in men 65 to 84 years old and women 75 to 84 years old with existing cardiovascular disease, where costs per QALY gained were below $50,000. 

  • Treating high-risk patients without prior cardiovascular disease was only intermediately cost-effective in most adults with baseline blood pressures 140/90 mm Hg or higher and not cost-effective in those with baseline blood pressures measuring 130-139/80-89 mm Hg.

“Previous studies have shown that compared with no treatment, treating high blood pressure according to the 2003 Seventh Report is cost-effective over 10 years,” Penko noted. “We were surprised to learn in our study that wasn’t the case for all patients indicated for medication treatment in the 2017 guidelines.”

“The study’s findings suggest an incremental approach to implementing the 2017 ACC/AHA hypertension guidelines, first focusing limited resources on treating the oldest, highest-risk adults to intensive blood pressure goals,” she said. “More research is needed to better understand the balance of treatment benefits and consequences over a lifetime of treatment, particularly in younger adults.”

For their analysis, the researchers used a long-tested computer simulation model, the Cardiovascular Disease Policy Model, to estimate treatment costs over a decade and the benefits to patients’ health by applying the 2017 guidelines first to U.S. adults with the highest risk of heart disease, and then, step-by-step, to lower-risk groups until the guidelines were fully implemented. Risk level was determined based on patients’ baseline blood pressure, history of heart disease or stroke (or a high risk score for a future cardiovascular problem) and sex and age group.

“This was a really neat simulation study. What they found in their analysis was that by reducing blood pressure to these new targets, there were some benefits that came about — reduction of cardiovascular events like stroke and heart attack, but there are also costs,” noted Mitchell S.V. Elkind, M.D., American Heart Association president-elect, Chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association, and professor of neurology and epidemiology at Columbia University in New York. “And, so there's always this balancing act. We'd like to lower blood pressure in as many people as possible, but we have to balance that with the costs, especially if you think about it on the population level. The benefits in terms of health outweighed the costs significantly, particularly for those who were older and had evidence of cardiovascular disease.”

Co-authors are Brandon K. Bellows, Pharm.D., M.S.; Gabriel S. Tajeu, Dr.P.H.; M.P.H.; David Guzman, M.S.P.H.; Pamela G. Coxson, Ph.D.; Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S.; and Andrew E. Moran, M.D., M.P.H. Author disclosures are in the abstract.

The study was funded by The National Heart, Lung, and Blood Institute.

Additional Resources:

Statements and conclusions of study authors presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at

The American Heart Association’s Scientific Sessions is a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians. Scientific Sessions 2019 is November 16-18 at the Pennsylvania Convention Center in Philadelphia. More than 12,000 leading physicians, scientists, cardiologists and allied health care professionals from around the world convene at the Scientific Sessions to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to over 4,100 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in the Scientific Sessions conversation on social media via #AHA19.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA Volunteer Expert Perspective:

AHA News Media in Dallas: 214-706-1173

AHA News Media Office, Nov. 16-18, 2019 at the Pennsylvania Convention Center, Philadelphia: 215-418-2450

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and